1.      Sakane H., Ishida M., Shi L., Fukumoto W., Sakai C., Miyata Y., Ishida T., Akita T., Okada M., Awai K., Tashiro S.: Biological Effects of Low-Dose Chest CT on Chromosomal DNA. Radiology. 2020 Mar 10:190389. doi: 10.1148/radiol.2020190389. [Epub ahead of print]

2.      Ohsawa M., Hamai Y., Emi M., Tanabe K., Okada M.: Thoracoscopic double-flap reconstruction for esophagogastric junction cancer: A case report. Int J Surg Case Rep. 2020 Jan 27;67:102-105.

3.      Ohsawa M., Hamai Y., Emi M., Takaoki F., Ibuki Y., Tomoaki K., Yoshikawa T., Okada M.: Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery. Anticancer Res. 2020 Feb;40(2):1153-1160.

4.      Mimae T., Tsutani Y., Miyata Y., Imai K., Ito H., Nakayama H., Ikeda N., Okada M.: Solid tumor size of 2 cm divides outcomes of patients with mixed ground glass opacity lung tumors. Ann Thorac Surg. 2020 Jan 22. pii: S0003-4975(20)30050-3. doi: 10.1016/j.athoracsur.2019.12.008. [Epub ahead of print]

5.      Kamigaichi A., Hamai Y., Emi M., Ibuki Y., Takahashi S., Katayama K., Furukawa T., Okada M.: Three-step surgical treatment of aortoesophageal fistula after thoracic endovascular aortic repair: A case report. Int J Surg Case Rep. 2019;65:221-224.

6.      Ito M., Codony-Servat C., Codony-Servat J., Lligé D., Chaib I., Sun X., Miao J., Sun R., Cai X., Verlicchi A., Okada M., Molina-Vila MA., Karachaliou N., Cao P., Rosell R.: Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Commun Signal. 2019 Oct 28;17(1):137.

7.      Kato K., Cho BC., Takahashi M., Okada M., Lin CY., Chin K., Kadowaki S., Ahn MJ., Hamamoto Y., Doki Y., Yen CC., Kubota Y., Kim SB., Hsu CH., Holtved E., Xynos I., Kodani M., Kitagawa Y.: Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Nov;20(11):1506-1517.

8.      Ohsawa M., Hamai Y., Ibuki Y., Emi M., Miyata Y., Okada M.: Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report. Anticancer Res.  2019 Aug;39(8):4399-4403.

9.      Okada M., Kijima T., Aoe K., Kato T., Fujimoto N., Nakagawa K., Takeda Y., Hida T., Kanai K., Imamura F., Oizumi S., Takahashi T., Takenoyama M., Tanaka H., Hirano J., Namba Y., Ohe Y.: Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019 Sep 15;25(18):5485-5492.

10.   Suzuki K., Saji H., Aokage K., Watanabe SI., Okada M., Mizusawa J., Nakajima R., Tsuboi M., Nakamura S., Nakamura K., Mitsudomi T., Asamura H. ; West Japan Oncology Group; Japan Clinical Oncology Group. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907.

11.   Saito H., Fukuhara T., Furuya N., Watanabe K., Sugawara S., Iwasawa S., Tsunezuka Y., Yamaguchi O., Okada M., Yoshimori K., Nakachi I., Gemma A., Azuma K., Kurimoto F., Tsubata Y., Fujita Y., Nagashima H., Asai G., Watanabe S., Miyazaki M., Hagiwara K., Nukiwa T., Morita S., Kobayashi K., Maemondo M.: Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635.

12.   Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H., Endo S., Natsugoe S., Doki Y., Hirata Y., Kobayashi J., Motomura N., Nakano K., Nishida H., Okada M., Saiki Y., Saito A., Sato Y., Tanemoto K., Toh Y., Tsukihara H., Wakui S., Yokomise H., Masuda M., Yokoi K., Okita Y.: Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019 Jun;67(6):573-575.

13.   Hiraoka E., Mimae T., Ito M., Kadoya T., Miyata Y., Ito A., Okada M.: Breast cancer cell motility is promoted by 14-3-3γ. Breast Cancer. 2019 Sep;26(5):581-593.

14.   Masuda T., Nakashima T., Namba M., Yamaguchi K., Sakamoto S., Horimasu Y., Miyamoto S., Iwamoto H., Fujitaka K., Miyata Y., Hamada H., Okada M., Hattori N.: Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med. 2019 Apr;23(4):2984-2994.

15.   Handa Y., Tsutani Y., Mimae T., Tasaki T., Miyata Y., Okada M.: Surgical Outcomes of Complex versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2019 Apr;107(4):1032-1039.

16.   Kubo M., Kawai M., Kumamaru H., Miyata H., Tamura K., Yoshida M., Ogo E., Nagahashi M., Asaga S., Kojima Y., Kadoya T., Aogi K., Niikura N., Miyashita M., Iijima K., Hayashi N., Yamamoto Y., Imoto S., Jinno H.: A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.Breast Cancer Res Treat. 2019 Dec;178(3):647-656. doi: 10.1007/s10549-019-05413-7.

17.   Ishiguro H., Ohno S., Yamamoto Y., Takao S., Sato N., Fujisawa T., Kadoya T., Kuroi K., Bando H., Teramura Y., Iwata H., Tanaka S., Toi M.: Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.

18.   Yoshiya T., Mimae T., Ito M., Sasada S., Tsutani Y., Satoh K.¹⁾, Masuda T.²⁾, Miyata Y., Hattori N.²⁾, Okada M. (1) The Center for Data Science Education and Research, Shiga University. 2)Department of Molecular and Internal Medicine, Hiroshima University).：Prospective, Randomized, Cross-Over Pilot Study of the Effects of Rikkunshito, a Japanese Traditional Herbal Medicine, on Anorexia and Plasma-Acylated Ghrelin Levels in Lung Cancer Patients Undergoing Cisplatin-Based Chemotherapy. Invest New Drugs doi: 10.1007/s10637-019-00836-x. Epub 2019 Aug 19.

19.   Mimae T., Okada M.: Are segmentectomy and lobectomy comparable in terms of curative intent for early stage non-small cell lung cancer? Gen Thorac Cardiovasc Surg. 2019 Nov 6.

20.   Sasada S., Masumoto N., Suzuki E., Sueoka S., Goda N., Kajitani K., Emi A., Kadoya T., Okada M. : Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT. Eur J Nucl Med Mol Imaging 46, 831-837, 2019. (I)

21.   Song H., Sasada S., Masumoto N., Kadoya T., Shiroma N., Orita M., Arihiro K., Okada M., Kikkawa T.: Detectability of Breast Tumors in Excised Breast Tissues of Total Mastectomy by IR-UWB-Radar-Based Breast Cancer Imaging. IEEE Trans Biomed Eng 66, 2296-2305, 2019. (I)

22.   Fukui K., Masumoto N., Shiroma N., Kanou A., Sasada S., Emi A., Kadoya T., Yokozaki M., Arihiro K., Okada M.: Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer 46, 573-580, 2019. (I)

23.   Sasada S., Shiroma N., Goda N., Kajitani K., Emi A., Masumoto N., Kadoya T., Arihiro K., Okada M.: The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer. Breast Cancer Res Treat 177, 651-657, 2019. (I)

24.   Sasada S., Masumoto N., Kimura Y., Kajitani K., Emi A., Kadoya T., Okada M.:  Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT. AJR Am J Roentgenol 213, 1129-1135, 2019. (I)

25.   Yunokawa M., Sasada S., Takehara Y., Takahashi K., Shimoi T., Yonemori K., Ishikawa M., Kato T., Tamura K.: Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan. Cancer Chemother Pharmacol 84, 1051-1058, 2019. (I)

26.   Yamakita I.¹⁾, Mimae T.¹⁾, Tsutani Y.¹⁾, Miyata Y.¹⁾, Ito A.²⁾, Okada M. ¹⁾, 1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, 2) Department of Pathology, Faculty of Medicine, Kinki University, Osaka, Japan：Guanylate binding protein 1 (GBP-1) promotes cell motility and invasiveness of lung adenocarcinoma. Biochemical and Biophysical Research Communications, 518(2):266-272, 2019.

27.   Ito M., Miyata Y., Tsutani Y., Ito H., Nakayama H., Imai K., Ikeda N., Okada M.: Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer. 2020 Mar;141:107-113. (I)

28.   Ohsawa M., Tsutani Y., Fujiwara M., Mimae T., Miyata Y., Okada M.: Predicting severe postoperative complication in patients with lung cancer and interstitial pneumonia. Ann Thorac Surg. Epub 2019 Dec 27. (I）

29.   Kishi N., Ito M., Miyata Y., Kanai A., Handa Y., Tsutani Y., Kushitani K., Takeshima Y., Okada M.: Intense expression of EGFR L858R characterizes the micropapillary component and L858R is associated with the risk of recurrence in pN0M0 lung adenocarcinoma with the micropapillary component. Ann Surg Oncol. 2020 Mar;27(3):945-955. (I)

30.   Tsutani Y., Kagimoto A., Handa Y., Mimae T., Miyata Y., Okada M.: Wedge resection versus segmentectomy in patients with stage I non-small-cell lung cancer unfit for lobectomy. Jpn J Clin Oncol. 2019 Dec 27;49(12):1134-1142. (I)

31.   Nakanishi Y., Masuda T., Yamaguchi K., Sakamoto S., Horimasu Y., Mimae T., Nakashima T., Miyamoto S., Tsutani Y., Iwamoto H., Fujitaka K., Miyata Y., Hamada H., Okada M., Hattori N.: Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. Int J Clin Oncol. 2020 Jan;25(1):74-81. (I)

32.   Tsutani Y., Suzuki K., Koike T., Wakabayashi M., Mizutani T., Aokage K., Saji H., Nakagawa K., Zenke T., Takamochi K., Ito H., Aoki T., Okami J., Yoshioka H., Okada M., Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group (JCOG-LCSSG). Ann Thorac Surg. 2019 Nov;108(5):1484-1490. (I)

33.   Ito M., Miyata Y., Hirano S., Kimura S., Irisuna F., Ikeda K., Kushitani K., Kishi N., Tsutani Y., Takeshima Y., Okada M.: Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. J Cancer Res Clin Oncol. 2019 Sep;145(9):2325-2333. (I)

34.   Kamigaichi A., Tsutani Y., Fujiwara M., Mimae T., Miyata Y., Okada M.: Postoperative recurrence and survival after segmentectomy for clinical stage 0 or IA lung cancer. Clin Lung Cancer. 2019 Sep;20(5):397-402.e1. (I)

35.   Nakanishi Y., Masuda T., Yamaguchi K., Sakamoto S., Horimasu Y., Nakashima T., Miyamoto S., Tsutani Y., Iwamoto H., Fujitaka K., Miyata Y., Hamada H., Okada M., Hattori N.: Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig. 2019 Sep;57(5):451-459. (I)

36.   Handa Y., Tsutani Y., Mimae T., Miyata Y., Okada M.: Complex segmentectomy in the treatment of stage IA nonsmall cell lung cancer.The European Journal of Cardio-Thoracic Surgery 2020;57(1):114-121.

37.   Handa Y., Tsutani Y., Shiroma N., Kai Y, Mimae T., Miyata Y., Takeshima Y., Arihiro K.,  Okada M.:Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Clinical Lung Cancer, In press.

38.   Hamai Y., Hihara J., Emi M., Ibuki Y., Murakami Y., Nishibuchi I., Nagata Y., Aoki Y., Furukawa T., Okada M.: Clinical Significance of 18 F-Fluorodeoxyglucose-Positron Emission Tomography-Positive Lymph Nodes to Outcomes of Trimodal Therapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 26: 1869-1878, 2019.

39.   Hamai Y., Emi M., Ibuki Y., Murakami Y., Nishibuchi I., Nagata Y., Furukawa T., Kurokawa T., Ohsawa M., Okada M.: Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma. Anticancer Res. 39: 1433-1440, 2019.

40.   Nakamura K., Urabe Y., Oka S., Ito M., Kotachi T., Ninomiya Y., Boda T., Hiyama T., Emi M., Hamai Y., Shiroma N., Tanaka S., Chayama K.: A Case of Primary Malignant Melanoma of the Esophagus With a Widely Expanded Surface Area. Clin J Gastroenterol. 12:424-428, 2019.

41.   Hamai Y., Yoshiya T., Hihara J., Emi M., Furukawa T., Yamakita I., Ibuki Y., Okada M.: Traditional Japanese Herbal Medicine Rikkunshito Increases Food Intake and Plasma Acylated Ghrelin Levels in Patients With Esophageal Cancer Treated by Cisplatin-Based Chemotherapy. J Thorac Dis. 11:2470-2478, 2019.

42.   Kimura Y., Sasada S., Goda N., Kajitani K., Emi A., Masumoto N., Kadoya T., Okada M.¹⁾ (1) Department of Breast Surgery, Hiroshima University Hospital): Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes. Journal of Radiation Oncology 8, 323–328(2019).

43.   Makidono K., Miyata Y., Ikeda T., Tsutani Y., Kushitani K., Takeshima Y., Okada M.: Investigation of surgical technique for bronchial stump closure after lobectomy in animal model. Gen Thorac Cardiovasc Surg. 2020 Jun;68(6):609-614.

44.   鍵本篤志, 三村剛史, 宮本竜弥,中島千佳, 山下芳典 : 外傷性胸骨骨折に対する早期の胸骨固定術. 胸部外科72巻13号 1076–9, 2019.

45.   恵美純子, 梶谷桂子, 春田るみ, 郷田紀子, 笹田伸介, 舛本法生, 片岡健, 角舎学行, 岡田守人 : 正しい乳癌知識の普及と検診率向上を目指して～女子高校生への出張講義の提案と課題. 日乳癌検診学会誌28(2): 89-92, 2019".